Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34+ hematopoietic stem cells: Implications for ex vivo tumor purging and autologous stem cell transplantation

Blood

Volumn 94, Issue 8, 1999, Pages 2901-2910

  LaCasse, E C ^b   Bray, M R ^b   Patterson, B ^b   Lim, W M ^b   Perampalam, S ^b   Radvanyi, L G ^b   Keating, A ^b   Stewart, A K ^b   Buckstein, R ^b   Sandhu, J S ^b   Miller, N ^b   Banerjee, D ^b   Singh, D ^b   Belch, A R ^b   Pilarski, L M ^b   Gariepy J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GLOBOTRIAOSYLCERAMIDE; RECEPTOR PROTEIN; RIBOSOME INACTIVATING PROTEIN; VEROTOXIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LYMPHOMA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; STEM CELL; STEM CELL TRANSPLANTATION; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BACTERIAL TOXINS; BIOLOGICAL MARKERS; BLOOD CELLS; BONE MARROW CELLS; BONE MARROW PURGING; BREAST NEOPLASMS; CARCINOMA; CELL SEPARATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; FEMALE; FLOW CYTOMETRY; GENES, IMMUNOGLOBULIN; GLYCOLIPIDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; ORGAN SPECIFICITY; PLASMA CELLS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SHIGA-LIKE TOXIN I; TRANSPLANTATION, AUTOLOGOUS; TRIHEXOSYLCERAMIDES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; TUMOR STEM CELLS;

EID: 13044254786     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Heslop HE, Rooney CM, Brenner MK: Gene-marking and haemopoietic stem-cell transplantation. Blood Rev 9:220, 1995
2. Stewart AK, Dube ID, Kamel-Reid S, Keating A: A phase 1 study of autologous bone marrow transplantation with stem cell gene marking in multiple myeloma. Hum Gene Ther 6:107, 1995
3. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard MJ, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525, 1991
4. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780, 1996
5. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT: Shiga toxin: Biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 180:65, 1992
6. Sandvig K, Van Deurs B: Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev 76:949, 1996
7. LaCasse EC, Saleh MT, Patterson B, Minden MD, Gariepy I: Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood 88:1561, 1996
8. Shears P: Shigella infections. Ann Trop Med Parasitol 90:105, 1996
9. Arbus GS: Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome. Kidney Int 51:S91, 1997 (suppl 58)
10. Hofmann SL: Southwestern internal medicine conference: Shiga-like toxins in hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Am J Med Sci 306:398, 1993
11. Keusch GT, Acheson DWK: Thrombotic thrombocytopenic purpura associated with Shiga toxins. Semin Hematol 34:106, 1997
12. Su C, Brandt LJ: Escherichia coli O157:H7 infections in humans. Ann Intern Med 123:698, 1995
13. van der Kar NCAJ, Monnens LAH, Karmali MA, van Hinsbergh VWM: Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80:2755, 1992
14. Yuhas Y, Weizman A, Dinari G, Ashkenazi S: An animal model for the study of neurotoxicity of bacterial products and application of the model to demonstrate that Shiga toxin and lipopolysaccharide cooperate in inducing neurologic disorders. J Infect Dis 171:1244, 1995
15. Appelbaum FR: The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. CA Cancer J Clin 46:142, 1996
16. Horowitz MM: Autologous bone marrow transplants for cancer, 1989-1993. J Natl Cancer Inst 86:1045, 1994
17. Sandhu JS, Clark BR, Boynton EL, Atkins H, Messner H, Keating A, Hozumi N: Human hematopoiesis in SCID mice implanted with adult cancellous bone. Blood 88:1973, 1996
18. Wiels J, Fellous M, Tursz T: A monoclonal antibody against a Burkitt's lymphoma associated antigen. Proc Natl Acad Sci USA 78:6485, 1981
19. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun R-X, Klein B, Dore J-M: A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94:318, 1996
20. Latza U, Niedobitek G, Schwarting G, Nekarda H, Stein H: Ber-EP4: New monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 43:213, 1990
21. Linsley PS, Brown JP, Magnani JL, Horn D: Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Cancer Res 48:2138, 1988
22. Deans JP, Wilkins JA, Caixia S, Pruski E, Pilarski LM: Prolonged expression of high molecular mass CD45RA isoform during the differentiation of human progenitor thymocytes to CD3+ cells in vitro. J Immunol 147:4060, 1991
23. Bergsagel PL, Masellis S, Szczepek A, Mant MJ, Belch AR, Pilarski LM: In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain. Blood 85:436, 1995
24. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM: A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. Blood 92:2844, 1998
25. Pilarski LM, Szczepek AJ, Belch AR: Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood 90:3751, 1997
26. Pilarski LM, Pruski E, Wizniak J, Paine D, Seeberger K, Mant MJ, Brown CB, Belch AR: Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Blood (in press)
27. Petric M, Karmali MA, Richardson S, Cheung R: Purification and biological properties of Escherichia coli verocytotoxin. FEMS Microbiol Lett 41:63, 1987
28. Ramotar K, Boyd B, Tyrrell G, Gariépy J, Lingwood C, Brunton J: Characterization of Shiga-like toxin 1 B-subunit purified from overproducing clones of the SLT-1 B cistron. Biochem J 272:805, 1990
29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107, 1990
30. Apostolopoulos V, McKenzie IFC: Cellular mucins: Targets for immunotherapy. Crit Rev Immunol 14:293, 1994
31. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Wandte RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
32. Cohen A, Madrio-Marina V, Estrov Z, Freedman MH, Lingwood CA, Dosch H-M: Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: A mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol 2:1, 1990
33. Ling NR, Hardie D, Lowe J, Johnson GD, Khan M, MacLennan ICM: A phenotypic study of cells from Burkitt lymphoma and EBV-B-lymphoblastoid lines and their relationship to cells in normal lymphoid tissues. Int J Cancer 43:112, 1989
34. Mangeney M, Richard Y, Coulaud D, Tursz T, Wiels J: CD77: An antigen of germinal center B cells entering apoptosis. Bur J Immunol 21:1131, 1991
35. Murray LJ, Habeshaw JA, Wiels J, Greaves MF: Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. Int J Cancer 36:561, 1985
36. Schwartz-Albiez R, Dörken B, Möller P, Brodin NT, Monner DA, Kniep B: Neutral glycosphingolipids of the globo-series characterize activation stages corresponding to germinal center B cells. Int Immunol 2:929, 1990
37. Wiels J, Tursz T: CD77 workshop panel report, in Schlossman SF, et al (eds): Leucocyte Typing V, vol 1. Oxford, UK, Oxford, 1995, p 597
38. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ: Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage. Br J Haematol 97:46, 1997
39. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM: CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ rearrangements. Blood 89:1824, 1997
40. Chin-Yee I, Keeney M, Anderson L, Nayar R, Sutherland DR: Current status of CD34+ cell analysis by flow cytometry: The ISHAGE guidelines. Clin Immunol Newslett 17:1, 1997
41. Sutherland DR, Anderson L, Keeney M, Nayar R Chin-Yee I: The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 5:213, 1996
42. Leibovitz A: Cell lines from human breast, in Hay RJ, Park J-G, Gazdar A (eds): Atlas of Human Tumor Cell Lines. San Diego, CA, Academic, 1994, p 161
43. k, CD77) produced with a synthetic glycoconjugate as immunogen: Reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors. Int J Cancer 48:848, 1991
44. Moller P, Mielke B: Extensive analysis of tissue distribution of antigens defined by new clustered and unclustered B-cell antibodies, in Knapp W, et al (eds): Leucocyte Typing IV. Oxford, UK, Oxford, 1989, p 175
45. Mechtersheimer G, Kruger KH, Born IA, Moller P: Antigenic profile of mammary fibroadenoma and cystosarcoma phyllodes: A study using antibodies to estrogen- and progesterone receptors and to a panel of cell surface molecules. Path Res Pract 186:427, 1990
46. Pallesen G, Zeuthen J: Distribution of the Burkitt's lymphoma-associated antigen (BLA) in normal human tissue and malignant lymphoma as defined by immunohistological staining with monoclonal antibody 38.13. J Cancer Res Clin Oncol 113:78, 1987
47. Newburg DS, Ashkenazi S, Cleary TG: Human milk contains the Shiga toxin and Shiga-like toxin receptor glycolipid Gb3. J Infect Dis 166:832, 1992
48. Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Karmagi R, Hakomori S-i: Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J Biol Chem 259:14773, 1984
49. Freedman AS, Nadler LM: Immunologic markers in B-cell chronic lymphocytic leukemia, in Cheson BD (ed): Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments, vol 1. Basic and Clinical Oncology. New York, NY, Marcel Dekker, 1993, p 1
50. Favrot MC, Philip I, Philip T, Portoukalian J, Dore JF, Lenoir GM: Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin. J Natl Cancer Inst 73:841, 1984
51. Gordon J, Mellstedt H, Åman P, Biderfeld P, Björkholm M, Klein G: Phenotypes in chronic B-lymphocytic leukemia probed by monoclonal antibodies and immunoglobulin secretion studies: Identification of stages of maturation arrest and the relation to clinical findings. Blood 62:910, 1983
52. Musclow E, Farkas-Himsley H: Bacteriocin and flow cytometry in laboratory diagnosis of leukemic peripheral blood lymphocytes and bone marrow cells. Eur J Cancer Clin Oncol 19:163, 1983
53. Zhang X-g, Gaillard JP, Robillard N, Lu Z-Y, Gu Z-J, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654, 1994
54. Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Française du Myelome. N Engl J Med 335:91, 1996
55. Spitalnik PF, Spitalnik SL: The P blood group system: Biochemical, serological, and clinical aspects. Transf Med Rev 9:110, 1995
56. Ramegowda B, Tesh VL: Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect Immun 64:1173, 1996
57. van Setten PA, Monnens LAH, Verstraten RGG, van den Heuvel LPWJ, van Hinsbergh VWM: Effects of verocytoloxin-1 on nonadherenl human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release. Blood 88:174, 1996
58. Bitzan M, Richardson S, Huang C, Boyd B, Petric M, Karmali MA: Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect Immun 62:3337, 1994
59. Koerner T, Weinfeld H, Bullard L, Williams L: Antibodies against platelet glycosphingolipids: Detection in serum by quantitative HPTLC-autoradiography and association with autoimmune and alloimmune processes. Blood 74:274, 1989